Compare PepsiCo, Inc. (PEP) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs ResMed Inc. — how do they compare? PepsiCo, Inc. trades at $125.99 (market cap $174.89B), while ResMed Inc. trades at $229.88 (market cap $31.89B). The key difference: PepsiCo, Inc. is far larger — about 5.5× ResMed Inc.'s market cap, and PepsiCo, Inc. pays the higher dividend (4.61%). Which is the better fit depends on your goals — on Pluang, investors hold PepsiCo, Inc. for 107 Days and ResMed Inc. for 51 Days on average.
| PEP | RMD | |
|---|---|---|
Market Cap | $174.89B | $31.89B |
Volume | 23,968,864 | 618,314 |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $277.88 |
52-Week Low | $123.64 | $182.82 |
Typical Hold Time | 107 Days | 51 Days |
Enterprise Value | $215.61B | $31.24B |
Dividend Yield | 4.61% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $125.80, up 1.74% today, with a bearish technical signal but strong fundamentals including four consecutive quarterly EPS beats. Revenue grew to $93.93B in 2025, with a net margin of 10.78% and robust cash flow. Analyst consensus is a Buy with a $146.77 price target, though recent news highlights pricing pressures in snacks.
The outlook is mixed: strong profitability and institutional support offer upside, but bearish technicals and consumer pushback on high prices pose near-term risks. Execution on North American turnaround and margin expansion will be critical for sustained growth amid competitive and macroeconomic challenges.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
